title: Evaluation of some biochemical markers as prognostic factors in malignant lymphomas.
abstract: This study aimed to estimate the pre- and post-treatment serum levels of glycosaminoglycans (GAGs), soluble p55 tumor necrosis factor receptor (sp55TNF-R) and soluble L-selectin in order to evaluate their prognostic significance and their role in monitoring tumor growth and host-tumor response in malignant lymphomas. Also, the work aimed to investigate the relationship between these levels with B symptoms and disease stage. For this purpose, 43 newly diagnosed patients with malignant lymphoma (12 with Hodgkin's disease (HD) and 31 with Non-Hodgkin's lymphoma (NHL) were selected from Mansoura University Hospital. Among NHL patients, 7 were in stage I/II, 13 in stage III and 14 in stage IV. In addition, 10 NHL patients were presented with B symptoms while, 21 did not. 7 apparently healthy individuals were selected as a control reference group.
  
  
  RESULTS
  1-Pre-treatment levels of GAGs, sp55TNF-R and sL-selectin increased significantly in both HD and NHL before treatment as compared to control. Pre-treatment sp55TNF-R levels in both diseases and sL-selectin (only in HD patients) may have a significant value in predicting response to therapy, while GAGs level in both diseases and sL-selectin in NHL patients had a limited value in such prediction. 2- In contrast to sp55TNF-R and sL-selectin, post-treatment GAG levels are thought to be a good sign of remission in both HD and NHL. 3- Serum GAG levels increased significantly before treatment in stages III/IV NHL as compared to stage I/II, so serum GAGs at diagnosis could reflect tumor bulk and the disease activity. 4- Elevated serum sp55TNF-R before treatment was associated with the presence of B symptoms and such association lead to a worse prognosis.
  
  
  CONCLUSIONS
  Pre-treatment sp55TNF-R levels in both HD & NHL and sL-selectin (only in HD patients) could be used as prognostic factor with respect to predicting treatment outcome. Serum GAGs at diagnosis could reflect tumor bulk and the disease activity.
authors.affiliation: Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Egypt.
authors.forename: Hala A
authors.initials: HA
authors.lastname: Salem
authors.forename: Laila A
authors.initials: LA
authors.lastname: Eissa
authors.forename: Ahmed M
authors.initials: AM
authors.lastname: Rabbie
authors.forename: L M
authors.initials: LM
authors.lastname: El-Helw
authors.forename: Amal M
authors.initials: AM
authors.lastname: El-Gayar
mesh_terms: D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor; D001772:Blood Cell Count; D001799:Blood Sedimentation; D005260:Female; D006025:Glycosaminoglycans / Q000378:metabolism; D006801:Humans; D007677:Kidney Function Tests; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D019041:L-Selectin / Q000378:metabolism; D008111:Liver Function Tests; D008223:Lymphoma / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D006025:Glycosaminoglycans; D047888:Receptors, Tumor Necrosis Factor, Type I; D019041:L-Selectin; D007770:L-Lactate Dehydrogenase